

Manufacturer


Obligations and transitional provisions for Swiss manufacturers

Dr Michael Köhli, Unit Head, Medical Devices Surveillance (MDS)

A natural or legal person who [...] markets [a] device under its name or trademark [...]

Definition of manufacturer, Art. 4 para. 1 let. e IvDO





Making available of a device under
own name

Change of intended purpose

Change that **could** affect the
conformity of the device

The quality management system
includes a concept of regulatory
compliance

Art. 43 IvDO, Art. 10 para. 8 let. a IVDR

Quality management system



Device conformity



Manufacturer's obligations





Post-market surveillance system

Transparency



 **SWISSmedic**



Common specifications (CS)
Designated standards
Pharmacopoeia






Clinical condition

Scientific
validity

Clinical performance
Performance studies

**Performance
evaluation**

Analytical
performance



Analyte



Device

A manufacturer must carry out a **conformity assessment procedure**

The manufacturer and importer must be able to prove that

- a conformity assessment procedure has been carried out
- the device conforms



Intended use



ANNEX VIII

CLASSIFICATION RULES

1. IMPLEMENTING RULES

1.1. Application of the classification rules shall be governed by the intended purpose of the devices.

1.2. If the device in question is intended to be used in combination with another device, the classification rules shall apply separately to each of the devices.

1.3. Accessories for an in v their own right separat

1.4. Software, which drives within the same class

If the software is inde its own right.

1.5. Calibrators intended to same class as the devi

1.6. Control materials with for one specific analyt class as the device.

1.7. The manufacturer shal plementation rules in

Medical Devices

Medical Device Coordination Group Document MDCG 2020-16

MDCG 2020-16 rev.1

Guidance on Classification Rules for *in vitro* Diagnostic Medical Devices under Regulation (EU) 2017/746

January 2022

This document has been endorsed by the Medical Device Coordination Group (MDCG) established by Article 103 of Regulation (EU) 2017/745. The MDCG is composed of representatives of all Member States and a representative of the European Commission chairs it. The document is not a European Commission document and it cannot be regarded as reflecting the official position of the European Commission. Any views expressed in this document are not legally binding and only the Court of Justice of the European Union can give binding interpretations of Union law.



IVD

D

C

B

A sterile


A

IVD
D
C
B
A sterile

Manufacturer

Notified body
NBxxxx

QMS
Design



CE_{XXXX}

D: “Batch release” *NBxxxx*

IVD
A



CE

Quality management system



Design
Performance evaluation
Risk management
...




Post-market surveillance
system



PMS plan

PMS report
A **B** - as required

PSUR
C D - 1 / yr



Legacy devices from 26 May 2022



Before
26 May 2022

**Significant
changes** in design
and intended
purpose



As old legislation



Legacy device
List A
List B
Lay use
“IVD others”

98/79/EC
certificate?

Class according
to IVDR?

no

yes

Placing on the market (PoM)
Expiry of certificate, no later than 26 May 2025

Further making available on the market
Deadline PoM + 1 year

Placing on the market (PoM)
until:

D	26.05.2025
C	26.05.2026
B	26.05.2027
A sterile	26.05.2027
A	<i>none</i>

**Further making available on
the market**
Deadline PoM + 1 year

Important: IVDs placed on the market in CH before 26 May 2022: Make available on the market until 26.05.2025

The post-market surveillance, [...] vigilance [and] registration of economic operators and of the devices themselves are subject to the provisions of the IvDO.

Placing on the market of devices that comply with the old legislation, Art. 82 para. 2 IvDO

Concept new regulation

Classes A, **B**, **C**, **D**

Conformity assessment

Post-market surveillance

Deadlines for legacy devices

Sources, references and information

IvDO

MDCG

IVDR

SMC

Manufacturer's obligations

Definition: [Art. 4 para. 1 let. e IvDO](#)

Obligations: [Art. 39-43 IvDO](#), Art. 10 IVDR

Assumption of manufacturer's obligations by third parties: Art. 16 paras. 1 and 2 IVDR

Notification to Swissmedic: [IVD notification \(swissmedic.ch\)](#)

General Safety and Performance Requirements (GSPR)

[Art. 6 IvDO](#), Annex I IVDR

Designated standards: [Art. 45 para. 4 TPA](#), information from [Switec](#)

Common specifications: [Art. 45 para. 4 TPA](#), see relevant [EU IVDR implementing regulations](#), currently [Implementing Regulation \(EU\) 2022/1107](#)

Performance evaluation

[Art. 39 para. 3 IvDO](#), Art. 56 and Annex XIII IVDR

Clinical evidence: MDCG 2022-2

Software: MDCG 2020-1

Classification

[Art. 14 IvDO](#), Annex VIII IVDR

Classification guidelines: MDCG 2020-16

Classification of software: MDCG 2019-11

Conformity assessment

[Art. 17 and 19 IvDO](#), Art. 48 and Annexes IX-XI IVDR

Class D verification by NB: MDCG 2022-3

Post-market surveillance

System: [Art. 49 and 50 IvDO](#), Art. 78 para. 3 IVDR

Post-market surveillance plan: [Art. 51 IvDO](#), Annex III para. 1 IVDR

Post-market surveillance report (A&B): [Art. 52 IvDO](#)

Safety report (C&D): Art. [53-55 IvDO](#)

Legacy devices: Transitional periods and manufacturers' obligations

[Art. 81 -82 IvDO](#)

Application of IVDR requirements to legacy devices: MDCG 2022-8

Significant changes: MDCG 2022-6

General questions: [Frequently Asked Questions on medical devices \(swissmedic.ch\)](#)

Note: This summary is for information purposes only and is not a complete summary of the relevant legal requirements.